0001800934-22-000001.txt : 20220323 0001800934-22-000001.hdr.sgml : 20220323 20220323131816 ACCESSION NUMBER: 0001800934-22-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220323 DATE AS OF CHANGE: 20220323 EFFECTIVENESS DATE: 20220323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Revel Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001800934 IRS NUMBER: 842338101 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-438594 FILM NUMBER: 22762690 BUSINESS ADDRESS: STREET 1: 953 INDIANA STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: 217-766-4292 MAIL ADDRESS: STREET 1: 953 INDIANA STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 D 1 primary_doc.xml X0708 D LIVE 0001800934 Revel Pharmaceuticals Inc. 2325 3rd Street San Francisco CA CALIFORNIA 94107 (217) 766-4292 DELAWARE None None Corporation true 2019 Aaron James Cravens c/o Revel Pharmaceuticals Inc. 2325 3rd Street San Francisco CA CALIFORNIA 94107 Executive Officer Director Patrick Burgermeister c/o Revel Pharmaceuticals Inc. 2325 3rd Street San Francisco CA CALIFORNIA 94107 Director Jennifer Cochran c/o Revel Pharmaceuticals Inc. 2325 3rd Street San Francisco CA CALIFORNIA 94107 Director Biotechnology Decline to Disclose 06b false 2022-02-23 false true false 0 5752538 5752538 0 Series Seed-2 Preferred Stock and the common stock issuable upon conversion thereof. false 3 0 0 0 false Revel Pharmaceuticals Inc. /s/Aaron James Cravens Aaron James Cravens Chief Executive Officer 2022-03-23